Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
73.95M
Cash
33.64M
Avg Qtr Burn
-5.361M
Short % of Float
3.72%
Insider Ownership
16.29%
Institutional Own.
18.97%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Olvi-Vec (Olvimulogene nanivacirepvec) + platinum-doublet + bevacizumab Details Cancer, Platinum-resistant ovarian cancer, Ovarian cancer | Phase 3 Data readout | |
Olvi-Vec (Olvimulogene nanivacirepvec) Details Cancer, Non-small cell lung carcinoma | Phase 2 Data readout | |
Olvi-Vec (Olvimulogene nanivacirepvec) Details Cancer, Small cell lung cancer | Phase 1/2 Data readout |